| Citation: |
HAN M X, LI Z, ZHANG Q L, et al. Evaluation of left ventricular deformation changes in patients underwent different doses of anthracycline chemotherapy using 3D speckle-tracking imaging[J]. Chin J Clin Med, 2024, 31(4): 559-564. DOI: 10.12025/j.issn.1008-6358.2024.20240471
|
To analyze the changes in left ventricular deformation function in patients with diffuse large B-cell lymphoma (DLBCL) treated with different doses of anthracycline chemotherapy using 3D speckle-tracking imaging (3D-STI).
66 DLBCL patients receiving anthracycline chemotherapy were enrolled. Based on the cumulative dose of anthracycline received, the patients were divided into a high-dose group (> 360 mg/m2, n＝39) and a low-dose group (≤360 mg/m2, n＝27). Patients underwent transthoracic echocardiography before chemotherapy and within one week after completion of the entire chemotherapy cycle. Left ventricular global longitudinal strain (LVGLS), left ventricular global circumferential strain (LVGCS), and other indices were analyzed using 3D-STI to assess changes in left ventricular deformation indices after chemotherapy and between two groups.
Compared to baseline, DLBCL patients showed significant reductions in LVGLS, LVGCS and left atrial global longitudinal strain (LAGLS) after treatment completion (P < 0.001). When comparing the high-dose group with the low-dose group, there was a significant increase in relative LVGCS change rate at the end of chemotherapy (21.12 [6.52, 35.37] vs 5.49 [﹣14.73, 27.01]; P＝0.03). However, there were no statistically significant differences in relative left ventricular ejection fraction (LVEF), LVGLS, LVGCS, LVEF change rate, or LVGLS change rate between the two groups.
3D-STI can be a potential method to identify the sub-clinical deterioration of left ventricular systolic function in patients received anthracycline chemotherapy, the difference of change rate of LVGCS may predict the variation of sub-clinical deterioration of left ventricular function between patients received high and low doses of anthracycline chemotherapy.
| [1] |
RASCHI E, DIEMBERGER I, COSMI B, et al. ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations[J]. Intern Emerg Med, 2018, 13(1): 1-9. DOI: 10.1007/s11739-017-1755-0
|
| [2] |
LANG R M, BADANO L P, TSANG W, et al. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography[J]. Eur Heart J Cardiovasc Imag, 2012, 13(1): 1-46. DOI: 10.1093/ehjci/jer316
|
| [3] |
PAI V B, NAHATA M C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention[J]. Drug Saf, 2000, 22(4): 263-302. DOI: 10.2165/00002018-200022040-00002
|
| [4] |
CARDINALE D, IACOPO F, CIPOLLA C M. Cardiotoxicity of anthracyclines[J]. Front Cardiovasc Med, 2020, 7: 26. DOI: 10.3389/fcvm.2020.00026
|
| [5] |
HENRIKSEN P A. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention[J]. Heart, 2018, 104(12): 971-977. DOI: 10.1136/heartjnl-2017-312103
|
| [6] |
SWAIN S M, WHALEY F S, EWER M S. Congestive heart failure in patients treated with doxorubicin[J]. Cancer, 2003, 97(11): 2869-2879. DOI: 10.1002/cncr.11407
|
| [7] |
ZAMORANO J L, LANCELLOTTI P, MUÑOZ D R, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(36): 2768-2801. DOI: 10.1093/eurheartj/ehw211
|
| [8] |
KAMPHUIS J A M, LINSCHOTEN M, CRAMER M J, et al. Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy[J]. Cardiooncology, 2020, 6: 23.
|
| [9] |
GILBERT S H, BENSON A P, LI P, et al. Regional localisation of left ventricular sheet structure: integration with current models of cardiac fibre, sheet and band structure[J]. Eur J Cardio Thorac Surg, 2007, 32(2): 231-249. DOI: 10.1016/j.ejcts.2007.03.032
|
| [10] |
WICKRAMASINGHE C D, NGUYEN K L, WATSON K E, et al. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity[J]. Future Oncol, 2016, 12(6): 855-870. DOI: 10.2217/fon.15.349
|
| [11] |
陈佳慧, 张楚婕, 沈毅辉, 等. 实时三维超声心动图评估高剂量蒽环类药物化疗后左心室形态及收缩同步性的临床研究: 5年回顾性随访[J]. 中国临床医学, 2021, 28(2): 145-151. DOI: 10.12025/j.issn.1008-6358.2021.20210323
CHEN J H, ZHANG C J, SHEN Y H, et al. Late detection of left ventricular mechanical dyssynchrony and impaired morphology after high dose of anthracycline chemotherapy using real-time three-dimensional echocardiography: a 5-year retrospective follow-up study[J]. Chin J Clin Med, 2021, 28(2): 145-151. DOI: 10.12025/j.issn.1008-6358.2021.20210323
|
| [12] |
SUERKEN C K, D'AGOSTINO R B Jr, JORDAN J H, et al. Simultaneous left ventricular volume and strain changes during chemotherapy associate with 2-year postchemotherapy measures of left ventricular ejection fraction[J]. J Am Heart Assoc, 2020, 9(2): e015400. DOI: 10.1161/JAHA.119.015400
|
| [13] |
赵睿, 沈毅辉, 张群岭, 等. 三维斑点追踪成像技术诊断淋巴瘤患者蒽环类药物化疗后早期右心室收缩功能改变[J]. 中国超声医学杂志, 2020, 36(6): 514-519. DOI: 10.3969/j.issn.1002-0101.2020.06.011
ZHAO R, SHEN Y H, ZHANG Q L, et al. Early changes of right ventricular function assessed with three-dimension speckle tracking imaging after anthracycline exposure[J]. Chin J Ultrasound Med, 2020, 36(6): 514-519. DOI: 10.3969/j.issn.1002-0101.2020.06.011
|
| [14] |
UPSHAW J N, FINKELMAN B, HUBBARD R A, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy[J]. JACC Cardiovasc Imag, 2020, 13(1): 198-210. DOI: 10.1016/j.jcmg.2019.07.018
|
DownLoad: